🏢 官网IRPODDQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:09:31·⚡ 决策 08-26 20:18:56 +1h09m·62.1 天前
Insulet宣布管理层将出席富国银行第21届年度医疗健康大会
这是一条纯粹的会议参会公告,不含任何新增事实(无产品、业绩、指引、订单、监管或战略信息),不构成任何方向的催化,Web/KB/行情均不可能改变'不做'的结论。
📄 原文PODD↗ 原文
Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technolo…
不做 Insulet Corporation(PODD.US)
纯例行会议参会公告,不含任何新增业务、财务、产品或监管信息,无方向性催化,无交易价值。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Insulet于2026年8月26日通过Business Wire发布IR新闻稿,宣布管理层将于9月9日出席富国银行第21届年度医疗健康大会并做演示。该公告属于上市公司例行投资者关系活动通知,不包含任何新产品发布、业绩数据、指引调整、订单/合同、监管进展或战略变化等可交易信息。此类会议参会公告是美股医疗板块每月数十条的常规IR通讯,历史上对股价无独立影响。无需进一步研究即可确定无交易机会。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无先例可参考,但事件本身不含催化信息,不影响结论
方向:会议参会公告类事件无独立价格影响,无需先例校准
涨幅量级:不适用
形态:不适用
工具调用 · 历史记录,结果未知(1 种)
- fetch_decision_experience · 结果未知
原文全文
展开原文 · 1,889 字
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD), the global leader in
tubeless insulin pump technology
with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21
st
Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time).
The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website:
investors.insulet.com/events
.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit
insulet.com
or
omnipod.com
.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.
Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com
Media:
Joan Campion
Vice President, External Communications
pr@insulet.com
Source: Insulet Corporation
Insulet Corporation (NASDAQ: PODD), the global leader in
tubeless insulin pump technology
with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21
st
Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time).
The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website:
investors.insulet.com/events
.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit
insulet.com
or
omnipod.com
.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.
Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com
Media:
Joan Campion
Vice President, External Communications
pr@insulet.com
Source: Insulet Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。